These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 21250861

  • 1. Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan.
    Ishii H, Iwase M, Seino H, Shuto Y, Atsumi Y.
    Curr Med Res Opin; 2011 Mar; 27(3):643-50. PubMed ID: 21250861
    [Abstract] [Full Text] [Related]

  • 2. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 3. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 4. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 5. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.
    Mukherjee AK, Reddy VS, Shah S, Jhingan AK, Ramakrishnan P, Prusty V, Singh NS.
    J Indian Med Assoc; 2009 Jul; 107(7):464-70. PubMed ID: 20112854
    [Abstract] [Full Text] [Related]

  • 6. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.
    Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
    [Abstract] [Full Text] [Related]

  • 7. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW.
    Clin Ther; 2007 Dec; 29 Suppl D():S135-44. PubMed ID: 18191065
    [Abstract] [Full Text] [Related]

  • 8. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 9. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C, Gilbride CJ.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [Abstract] [Full Text] [Related]

  • 10. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 11. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M.
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [Abstract] [Full Text] [Related]

  • 12. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 13. Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus.
    Braun A, Sämann A, Kubiak T, Zieschang T, Kloos C, Müller UA, Oster P, Wolf G, Schiel R.
    Patient Educ Couns; 2008 Oct; 73(1):50-9. PubMed ID: 18583087
    [Abstract] [Full Text] [Related]

  • 14. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 15. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Jan; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 16. [Patient satisfaction in diabetes mellitus--measures and results].
    Kohlmann T, Moock J.
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S120-3; discussion S124-6. PubMed ID: 18686221
    [Abstract] [Full Text] [Related]

  • 17. Study design and baseline characteristics of patients in the PRESENT study.
    Shestakova M, Bech OM, Momani MS.
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S3-9. PubMed ID: 18672309
    [Abstract] [Full Text] [Related]

  • 18. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes.
    Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G, QuoLITy Study Group.
    Nutr Metab Cardiovasc Dis; 2009 Jan; 19(1):45-53. PubMed ID: 18450436
    [Abstract] [Full Text] [Related]

  • 19. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
    Yang W, Gao Y, Liu G, Chen L, Fu Z, Zou D, Feng P, Zhao Z.
    Curr Med Res Opin; 2010 Jan; 26(1):101-7. PubMed ID: 19916705
    [Abstract] [Full Text] [Related]

  • 20. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.